Background Hair loss/thinning is a common side effect of tamoxifen in estrogen receptor (ER) positive breast cancer therapy
Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that
This study determined whether the effect of FS, alone or in combination with TAM, is dose dependent, and it explored the potential
Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treatment of breast cancer and the development of resistance represents a major obstacle for a cure
Support is provided to the combination of quercetin and tamoxifen on human ER‐positive breast carcinoma management by regulated the gene expression involved in cell metastasis, cycle, and apoptosis through the ER pathways
Pituitary
Treatment with estrogen and with tamoxifen enhances SUMOylation required for transcriptional activity
A concomitant increase in the expression of the TSP-1 receptors alphavbeta3 and integrin-associated protein (IAP) occurs under these conditions, and antibodies to TSP-1
Downregulation of estrogen receptor alpha (ERα) is an important mechanism of tamoxifen resistance
Moreover, the positive response is usually of short duration, and most tumors eventually dev
The 66 kDa estrogen receptor alpha (ERα66) is the main molecular target for endocrine therapy such as tamoxifen treatment
The treatments of patients with ERα+ (estrogen receptor α) breast cancer are mainly endocrine therapies, such as tamoxifen and aromatase inhibitors that are both very efficient in reducing the risk of cancer recurrence in women 2 but also in men
Diagrammatic representation of effects of an antiestrogen and an aromatase inhibitor on prevention of breast cancer
This bioactive compound has significant experimental evidence for bioactivity in breast chemoprevention
Clin Cancer Res 2004;10:7703-11
Like SERMs, fulvestrant binds to the estrogen receptor and functions as